Close Menu

Memorial Sloan-Kettering

The collaborations will evaluate whether patient-specific ex vivo cancer immunotherapy assays can predict in vivo efficacy, and ACEA's cell analysis platform.

More than a third of the first 10,000 patients receiving MSK-IMPACT harbored actionable mutations, and 11 percent of the first 5,000 enrolled in a clinical trial. 

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Scientists at Memorial Sloan Kettering Cancer Center, led by Gabriela Chiosis, revealed how the complexes are important for tumor survival in certain cases.

Pages